We prospectively evaluated whether gadoxetic acid (Gd-EOB-DTPA) administration for liver magnetic resonance (MR) imaging affects the quantification of hepatic steatosis using MR spectroscopy (MRS). Materials and Methods: A total of 155 patients were included, who underwent gadoxetic acid-enhanced liver MR imaging and MRS during a 5-month period. Fast breath-hold high-speed T2-corrected multi-echo MRS was used before, and 20 min after, gadoxetic acid injection. The same location was maintained in the pre-contrast and post-contrast MRS. Changes in the fat fraction (FF) were compared between the pre-and post-contrast MRS using a paired t-test. The change in FF between cirrhotic and non-cirrhotic patients was compared using an independent t-test. In cirrhotic patients, the correlation between FF change and biochemical marker using Pearson's correlation test, was evaluated. Results: The mean FF in the post-contrast MRS (5.05 ± 5.26%) was significantly higher than in the pre-contrast MRS (4.77 ± 0.57%) (p < 0.000). The FF change between pre-contrast and post-contrast MRS was significantly higher in non-cirrhotic patients (0.41 ± 0.77%) than in cirrhotic patients (0.14 ± 0.59) (p = 0.010). Albumin and alkaline phosphatase shows weak correlation with FF change (both p < 0.02). Conclusion: Gadoxetic acid affects the quantification of hepatic steatosis by MRS. Hence, MRS should be performed before gadoxetic acid injection, particularly in noncirrhotic patients.
INTRODUCTION
Hepatic steatosis disease affects 10-30% of the general population across all ethnicities and age groups (1) (2) (3) (4) (5) . This condition is associated with insulin resistance, type 2 diabetes mellitus, and hyperlipidemia (1, 6) . Until the last few decades, hepatic steatosis was considered to be a relatively benign and common condition (7) . However, hepatic steatosis has the potential to progress to fibrosis, cirrhosis, and hepatocellular carcinoma. The diagnosis may be missed in some individuals because many patients with hepatic steatosis are asymptomatic (8) . The initial detection and precise quantification of hepatic steatosis disease is crucial for the successful management of these patients (1, 9) .
The current gold standard methods for the detection and quantification of hepatic steatosis are liver biopsy and magnetic resonance spectroscopy (MRS) (10, 11) . Liver biopsy has several disadvantages, such as the invasiveness of the procedure, risk of infection, and potential for hemorrhage (7) ; therefore liver biopsy alone is not recommended for identifying hepatic steatosis disease. MRS measures the chemical composition of a tissue di-
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Gadoxetic Acid가 자기공명분광술을 이용한 지방간의 정량화에 미치는 영향: 전향적 분석 rectly and non-invasively (12, 13) . Recently, MRS showed a strong and significant correlation with lipid content, and is regarded as the most accurate practical method for measuring liver fat in clinical practice (14) .
Gadoxetic acid (Gd-EOB-DTPA), which offers an innovative option for imaging the liver, is used for improved medical diagnosis with MR imaging. Gadoxetic acid is believed to be actively taken up in hepatocytes by a canalicular multispecific organic anion transporter 8 (15) . Approximately 50% of the injected dose of gadoxetic acid is taken up by hepatocytes and subsequently excreted into the biliary canaliculi (16) . Peak enhancement of gadoxetic acid is obtained 20 minutes after injection (17) , and hepatobiliary phase imaging is performed at this time (15) .
A previous study reported that gadoxetic acid does not show a significant effect on measuring fat fractions (FF) between precontrast MRS and post-contrast MRS (18) . The study had a relatively small sample size and was limited by the retrospective design. Since gadoxetic acid does not affect proton MRS, it could be performed during the interval of the dynamic phase to save time.
Therefore, the purpose of this study was to prospectively evaluate whether gadoxetic acid administration for liver MR imaging affects the hepatic steatosis quantification using MRS.
MATERIALS AND METHODS

Patients
This prospective study was approved by the institutional review board of Chonnam National University Hwasun Hospital.
Written informed consent was obtained from all patients. In January 2015, a pilot study including 41 patients was conducted to determine feasibility. The mean FF change was 0.27 ± 0.57%.
We assumed that a p < 0.01 was acceptable with a study power of 95%. The estimated sample size was 83 patients, using a onesample design. Between February 2015 and June 2015, individuals who were clinically suspected of having focal hepatic lesions were evaluated (Fig. 1) . Criteria for inclusion were: 1) age-between 20 to 85 years; 2) exclusion of contraindications to enhanced MR imaging (claustrophobia, metal implants, or pacemakers); and 3) absence of any history of transarterial chemoembolization, radiofrequency ablation, and hepatectomy. After analyzing the abdominal MR images, the following patients were excluded: patients who had diffuse or disseminated hepatic lesions [infiltrative or multinodular hepatocellular carcinoma (HCC), n = 20; disseminated metastasis, n = 10; numerous cysts n = 3, uneven fatty infiltration, n = 2] or large lesions replacing liver parenchyma (HCC, n = 5; hemangioma, n = 2), and patients (n = 35) who were not able to hold their breath sufficiently or for whom it was difficult to select a voxel for the analysis. were class A, 6 were class B, and 1 was class C. The other 78 patients were grouped as non-cirrhotic. This group showed no evidence of liver cirrhosis in physical findings, biochemical tests, and radiological imaging features. Hepatic metastasis was detected in 4 patients of the non-cirrhotic group. They were not excluded due to small size and peripheral location of metastasis.
MR imaging and MRS
MR imaging and MRS were performed concomitantly using a 3.0-T unit (MAGNETOM Skyra; Siemens, Erlangen, Germany). Three plain localizers were used to plan the MRS, and the The MR data were analyzed by off-line software from the MR vendor. At the echo time, the water (4.7 ppm) and fat (0.9, 1.3, 2.1, and 2.75 ppm) peaks were measured. Each measurable peak area was individually corrected for the T2 decay using nonlinear least-square fits, to determine their relative proton densities. The relative proton densities of the fat peaks located underneath the water peaks were determined according to Hamilton et al. (19) . The total proton density was defined as the sum of all T2-corrected individual fat peaks. The proton density FF was calculated as the ratio of the fat proton density to the sum of the fat and water proton densities (Fig. 2) .
Biochemical Studies
Common biochemical parameters were considered for serum markers, such as creatinine, urea, albumin, prothrombin time, (20) . In all patients, the serum markers were measured in the same laboratory and on the same day that the MR imaging was performed.
Statistical Analysis
The changes in the calculated FF between the pre-contrast MRS and the post-contrast MRS were compared using the paired t-test. The FF change between the cirrhotic group and the non- Proton of fat appears as several peaks, including a diacyl peak at 2.75 ppm (1), an α-olefinic and α-carboxyl peak at 2.1 ppm (2), a methylene peak at 1.3 ppm (3), and a methyl peak at 0.9 ppm (4). Whereas, proton in water appears as a single peak at 4.7 ppm. Fat fraction can be calculated as (Sum of fat peaks) / (Sum of fat peaks + water peak). 
RESULTS
The mean FFs of the entire study population in pre-contrast and post-contrast MRS are shown in Table 1 Table 2 . In the liver cirrhosis group, APH and albumin show weak correlation with the FF change (Fig. 5 ).
DISCUSSION
The mean FF was 4.77 ± 5.07% and 5.05 ± 5.26% on pre-contrast and post-contrast MRS, respectively. There was a significant change in the FF between the pre-and post-contrast MRS (p < 0.000). This suggests that gadoxetic acid influences the hepatic steatosis quantification using MRS. In post-contrast MRS, mean FF was more exaggerated than pre-contrast MRS by 0.28 ± 0.65%. Since MRS performed after gadoxetic acid enhanced the MR sequence, overestimation of FF and resultant false-positive diagnosis can be obtained. In the clinical field this can be negligible, thus making it insignificant whether hepatic quantification using MRS is performed before or after gadoxetic acid administration. However, for precise examination, hepatic steatosis quantification using MRS should be performed before A previous study, which used the same MR scanner with a similar protocol, showed that the mean FF was 6.50 ± 0.51% on pre-contrast MRS, and 6.70 ± 6.61% on post-contrast MRS.
However, a significant difference was not observed in the mean FF between the pre-and post-contrast MRS (18) . The mean FF changes between the pre-and post-contrast MRS showed a slight difference of 0.20% in a previous study and of 0.28% in our study. Compared to the previous study, our study differed in two points. First, the size of the cohort in our study was double than of the previous study. Second, our prospective study had stricter inclusion and exclusion criteria. Hence, our data would be more reliable due to the difference in the size of the sample and the characteristics of the cohort in our study.
As shown in Fig. 2 , the MRS spectra of the liver reveals a single peak of proton in water appearing at 4.7 ppm, and multiple peaks of proton in triglyceride appear at 1.3 ppm (methylene), 0.9 ppm (methyl), 2.1 ppm (α-olefinic and α-carboxyl), and 2.75 ppm (diacyl) (12, 19) . In Fig. 6 , predicted MRS spectra of gadoxetic acid
shows several peaks at similar frequency at 1. Thus, we can explain that calculated FF of liver could be overestimated by overlapped fat spectra of gadoxetic acid.
Impaired gadoxetic acid uptake and transport mechanisms in cirrhotic liver reduce the liver parenchymal enhancement (21) .
Impaired uptake by hepatocytes in cirrhotic liver tissue may reduce the change in FF detected between pre-and post-contrast MRS. In our study, the change in FF in the non-cirrhotic group between the pre-and post-contrast MRS was significantly higher than that of the cirrhotic group. Although the severity of cirrhosis can be assessed by measuring the relative enhancement of gadoxetic acid (22) , our data showed that it cannot be assessed by the FF change between pre-contrast and post-contrast MRS.
We observed a non-significant difference of approximately 0.9% in the FF change between patients with mild liver cirrhosis (Child A) and those with moderate to severe liver cirrhosis (Child B and C). This result may be related to the very small proportion of patients with severe liver cirrhosis, in our inclusion cohort. Therefore, we expect that a future study which includes more patients with moderate to severe liver cirrhosis will demonstrate a correlation between the FF change and the severity of liver cirrhosis.
Several studies have investigated the clinical or histologic factors that cause decreased hepatic enhancement on gadoxetic acid-enhanced MR imaging (22) (23) (24) (25) (26) . Among various parameters, the indocyanine green retention rate, AST, platelet count, prothrombin activity, total bilirubin, albumin, sodium, MELD score, MELD-Na score, Child-Pugh score, and the presence of ascites are important factors correlated with liver enhancement (22) (23) (24) (25) (26) . We expected that these parameters may be correlated with the change in the calculated FF. In total cohort, none of these biochemical markers showed a significant correlation with the FF change. However, APH shows a weak negative correlation, and albumin shows a weak positive correlation, with the FF change. These results support that impaired hepatocyte function may reduce the FF change as well as reduce the liver parenchymal enhancement.
Our study has several limitations. First, the proportion of patients with severe liver cirrhosis was relatively small. Only 9% of cirrhosis patients are Child-Pugh classification B or C. We suspect that the insufficient number of patients with severe cirrhosis prevented the detection of a significant change in FF among the Child Pugh classifications, and significant correlation of FF change with most of biochemical markers. Second, the location of the region of interest was slightly different between the preand post-contrast MRS. In spite of our effort to instruct the patients to hold their breath to the same degree, minor differences were inevitable. To overcome this limitation, several patients with an insufficient ability to hold their breath were excluded.
Third, this study did not yield reproducible analysis . We performed MRS just two times in a patient, once before and once after administration of gadoxetic acid, because several recent studies demonstrated good reproducibility and feasibility of hepatic fat quantification using MRS (10, 18, 27 ).
In conclusion, gadoxetic acid influenced hepatic steatosis quantification using MRS. Our results suggest that there is a risk Fig. 6 . Molecular structure and predicted MR spectra of gadoxetic acid. Several peaks (*) are located in similar frequencies with triglyceride in hepatocyte (Fig. 2) . We hypothesize that these peaks may produce overestimation of fat fraction on post-contrast MRS. MRS = magnetic resonance spectroscopy 
